Answers are grounded in this paper and cite their sources.
These findings suggest that triptolide is a promising agent to overcome STI571-resistant CML cells, and warrant a clinical trial of triptolide derivatives for CML with Bcr-Abl-T315I mutation.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: